Cabaletta Bio, Inc. (CABA) stock
CABANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.28−0.05 (-3.76%)
Close on Nov 13, 2026Market cap $217.02MP/E –Yield –
Cabaletta Bio total assets
Total assets on the balance sheet at the end of each period.
Cabaletta Bio's total assets was $336.49M at Sep 30, 2026. For fiscal 2025 it was $165.08M, down 10.8% from the year before. The highest annual figure on record is $253.65M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $165.08M | -10.8% |
| FY2024 | Dec 31, 2024 | $185.05M | -27.0% |
| FY2023 | Dec 31, 2023 | $253.65M | +116.9% |
| FY2022 | Dec 31, 2022 | $116.97M | -7.4% |
| FY2021 | Dec 31, 2021 | $126.34M | +10.1% |
| FY2020 | Dec 31, 2020 | $114.72M | -18.9% |
| FY2019 | Dec 31, 2019 | $141.47M | +314.0% |
| FY2018 | Dec 31, 2018 | $34.17M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $336.49M | +77.3% |
| Q2 FY2026 | Jun 30, 2026 | $256.73M | +14.4% |
| Q1 FY2026 | Mar 31, 2026 | $148.15M | -10.3% |
| Q4 FY2025 | Dec 31, 2025 | $165.08M | -10.8% |
| Q3 FY2025 | Sep 30, 2025 | $189.76M | -7.2% |
| Q2 FY2025 | Jun 30, 2025 | $224.50M | +3.3% |
| Q1 FY2025 | Mar 31, 2025 | $165.14M | -31.3% |
| Q4 FY2024 | Dec 31, 2024 | $185.05M | -27.0% |
| Q3 FY2024 | Sep 30, 2024 | $204.41M | +18.0% |
| Q2 FY2024 | Jun 30, 2024 | $217.42M | +17.8% |
| Q1 FY2024 | Mar 31, 2024 | $240.46M | +132.4% |
| Q4 FY2023 | Dec 31, 2023 | $253.65M | +116.9% |
| Q3 FY2023 | Sep 30, 2023 | $173.29M | +89.0% |
| Q2 FY2023 | Jun 30, 2023 | $184.64M | +81.0% |
| Q1 FY2023 | Mar 31, 2023 | $103.45M | -9.0% |
| Q4 FY2022 | Dec 31, 2022 | $116.97M | -7.4% |
| Q3 FY2022 | Sep 30, 2022 | $91.68M | -25.2% |
| Q2 FY2022 | Jun 30, 2022 | $102.02M | -4.6% |
| Q1 FY2022 | Mar 31, 2022 | $113.66M | +5.9% |
| Q4 FY2021 | Dec 31, 2021 | $126.34M | +10.1% |
| Q3 FY2021 | Sep 30, 2021 | $122.64M | +0.7% |
| Q2 FY2021 | Jun 30, 2021 | $106.93M | -16.4% |
| Q1 FY2021 | Mar 31, 2021 | $107.28M | -20.5% |
| Q4 FY2020 | Dec 31, 2020 | $114.72M | -18.9% |
| Q3 FY2020 | Sep 30, 2020 | $121.77M | +62.5% |
| Q2 FY2020 | Jun 30, 2020 | $127.90M | +274.3% |
| Q1 FY2020 | Mar 31, 2020 | $134.97M | – |
| Q4 FY2019 | Dec 31, 2019 | $141.47M | – |
| Q3 FY2019 | Sep 30, 2019 | $74.94M | – |
| Q4 FY2018 | Dec 31, 2018 | $34.17M | – |
See a number that looks wrong?